Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
Hidenori Takahashi, Yoshinobu Iwasaki, Takayasu Watanabe, Naoki Ichinose, Yasusei Okada, Akito Oiwa, Takehiro Kobayashi, Mariko Moriya, Toshimi Oda
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured.
Topics & Concepts
FavipiravirMedicinePneumoniaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Acute respiratory distressOutbreakCoronavirus disease 2019 (COVID-19)BetacoronavirusCoronavirusSevere acute respiratory syndrome2019-20 coronavirus outbreakRespiratory distressIntensive care medicineVirologyInternal medicineAnesthesiaDiseaseLungInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19